Valuation: OSE Immunotherapeutics

Market Cap 60.73M 69.49M 57.08M 52.09M 97.76M 6.64B 97.77M 685M 264M 3.39B 261M 255M 10.94B P/E 2026 *
-1.98x
P/E 2027 * -2.27x
Enterprise Value 102M 116M 95.41M 87.07M 163M 11.11B 163M 1.15B 442M 5.67B 436M 427M 18.28B EV / Sales 2026 *
20.7x
EV / Sales 2027 * 11.8x
Free-Float
78.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: OSE Immunotherapeutics

1 week-3.24%
Current month-19.59%
1 month-22.45%
3 months-24.46%
6 months-24.46%
Current year-49.06%
1 week 2.54
Extreme 2.538
2.72
1 month 2.54
Extreme 2.538
3.31
3 years 2.54
Extreme 2.538
10.74
5 years 2.54
Extreme 2.538
11.68
10 years 2.54
Extreme 2.538
15.15
Manager TitleAgeSince
Chief Executive Officer - 02/10/2025
Director of Finance/CFO 43 20/08/2025
Chief Tech/Sci/R&D Officer - 20/12/2021
Director TitleAgeSince
Director/Board Member 77 31/05/2016
Director/Board Member 73 14/06/2017
Director/Board Member - 22/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%-4.43%-56.29%-41.92% 69.87M
+2.55%+5.35%+3.61%+32.02% 46.68B
+0.08%+1.66%+44.26%+35.60% 44.42B
+0.05%-5.97%+342.95%+532.74% 41.32B
+0.66%+4.03%+10.07%+96.02% 41.58B
-1.60%-0.17%+9.73%+43.63% 30.14B
+0.96%+5.84%+26.39%+161.70% 17.42B
-0.01%-10.32% - - 15.6B
+1.15%+9.42%+26.21%+42.84% 15.54B
-1.08%+24.08%-12.52% - 14.08B
Average +0.28%+3.39%+43.82%+112.83% 29.64B
Weighted average by Cap. +0.42%+1.94%+70.46%+142.83%

Financials

2026 *2027 *
Net sales 4.9M 5.61M 4.61M 4.2M 7.89M 536M 7.89M 55.27M 21.33M 274M 21.06M 20.6M 882M 10.53M 12.05M 9.9M 9.03M 16.95M 1.15B 16.95M 119M 45.83M 588M 45.25M 44.26M 1.9B
Net income -30.59M -35M -28.75M -26.23M -49.23M -3.35B -49.24M -345M -133M -1.71B -131M -129M -5.51B -21.47M -24.56M -20.18M -18.41M -34.56M -2.35B -34.56M -242M -93.44M -1.2B -92.25M -90.23M -3.87B
Net Debt 40.79M 46.68M 38.34M 34.99M 65.66M 4.46B 65.67M 460M 178M 2.28B 175M 171M 7.35B 63.08M 72.19M 59.29M 54.11M 102M 6.9B 102M 712M 275M 3.52B 271M 265M 11.36B
Logo OSE Immunotherapeutics
OSE Immunotherapeutics develops first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). The Company's current well-balanced first-in-class clinical pipeline includes: - Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors; - OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors; - OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia; - FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes); - BI 765063/BI 770371 (anti-SIRP? mAb): partnership with Boehringer Ingelheim in advanced solid tumors. OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms: - Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I; - Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO; - Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.
Employees
-
Date Price Change
22/09/26 2.570 -0.62%
21/09/26 €2.586 -0.23%
18/09/26 €2.592 -1.67%
17/09/26 €2.636 +2.09%
16/09/26 €2.582 -2.79%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.590EUR
Average target price
12.70EUR
Spread / Average Target
+390.35%

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!